Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities-Reference-Cited by-同舟云学术

Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities

Published:2019-11-01 Issue:21 Volume:3 Page:3307-3321
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Cardin Sophie¹,Bilodeau Mélanie¹^ORCID,Roussy Mathieu¹²³,Aubert Léo⁴⁵,Milan Thomas⁶,Jouan Loubna⁷,Rouette Alexandre⁷,Laramée Louise¹,Gendron Patrick⁵⁸^ORCID,Duchaine Jean⁵,Decaluwe Hélène¹⁵,Spinella Jean-François¹⁵^ORCID,Mourad Stéphanie¹,Couture Françoise¹,Sinnett Daniel¹⁵,Haddad Élie¹⁵⁹^ORCID,Landry Josette-Renée¹⁵¹⁰,Ma Jing¹¹,Humphries R. Keith¹²,Roux Philippe P.⁶⁵¹³^ORCID,Hébert Josée⁵⁵¹⁴¹⁵,Gruber Tanja A.¹⁶,Wilhelm Brian T.⁵⁶,Cellot Sonia¹⁵¹⁵^ORCID

Affiliation:

1. Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine Research Center, Montréal, QC, Canada;

2. Department of Biomedical Sciences,

3. Faculty of Medicine,

4. Cell Signaling and Proteomics Research Unit, and

5. Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada;

6. Laboratory for High-Throughput Biology, Institute for Research in Immunology and Cancer, Montréal, QC, Canada;

7. Integrated Centre for Pediatric Clinical Genomics, CHU Sainte-Justine Research Center, Montréal, QC, Canada;

8. Bioinformatics Platform, Université de Montréal, Montréal, QC, Canada;

9. Department of Microbiology, Infectiology and Immunology, CHU Sainte-Justine, Montréal, QC, Canada;

10. Streamline Genomics, Montréal, QC, Canada;

11. Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN;

12. British Columbia Cancer Agency, Vancouver, BC, Canada;

13. Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada;

14. Division of Hematology, and

15. Québec Leukemia Cell Bank, Maisonneuve-Rosemont Hospital, Montréal, QC, Canada; and

16. Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN

Abstract

Key PointsEngineered human models of high-fatality pediatric leukemia are relevant to uncover disease biomarkers and therapeutic vulnerabilities. NUP98-KDM5A–associated AMKL expresses SELP, MPIG6B, and NEO1 biomarkers and is sensitive to pharmacologic inhibition with ruxolitinib.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/21/3307/1504683/advances030981.pdf

Reference51 articles.

1. Acute megakaryoblastic leukemia: experience of GIMEMA trials;Pagano;Leukemia,2002

2. The biology of pediatric acute megakaryoblastic leukemia;Gruber;Blood,2015

3. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update;Bhatnagar;Curr Hematol Malig Rep,2016

4. Origins of leukaemia in children with Down syndrome;Hitzler;Nat Rev Cancer,2005

5. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution’s experience;Athale;Blood,2001

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The emerging roles of histone demethylases in cancers;Cancer and Metastasis Reviews;2024-01-16

2. Clinical whole-genome sequencing and FISH identify two different fusion partners for NUP98 in a patient with acute myeloid leukemia: A case report;Cancer Genetics;2024-01

3. CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216;Blood Advances;2023-12-28

4. Advances in molecular characterization of pediatric acute megakaryoblastic leukemia not associated with Down syndrome; impact on therapy development;Frontiers in Cell and Developmental Biology;2023-06-01

5. Inhibitors of Jumonji-C domain-containing histone demethylases;Epigenetic Cancer Therapy;2023